文献速递膀胱癌与上尿路尿路上皮癌

膀胱内吉西他滨联合多西他赛一线治疗BCG初治高危非肌层浸润性尿路上皮癌的2期试验:3年更新结果

Phase 2 Trial of Intravesical Gemcitabine and Docetaxel as First-Line Treatment of Bacillus Calmette-Guérin‒Naïve Nonmuscle-Invasive Urothelial Carcinoma: Updated, 3-Year Outcomes.
PubMed 文献 · J Urol · 2026-06-22

这项前瞻性单臂开放标签2期试验评估膀胱内吉西他滨联合多西他赛(Gem/Doce)一线治疗BCG初治高危非肌层浸润性膀胱癌(NMIBC)的疗效。25例患者接受6周诱导后2年维持治疗,中位随访50个月,24个月和36个月高级别无复发生存率分别为84%和80%。结论提示该方案在这小样本队列中具有持续疗效和耐久性。

要点

  • BCG初治高危NMIBC患者接受Gem/Doce一线治疗,36个月高级别无复发生存率为80%。
  • 治疗期间无进展,2例(8%)行膀胱切除术。
  • 3级不良事件发生率为20%,包括血尿和尿路感染。

核心结论

  • 更新3年结果提示膀胱内Gem/Doce对BCG初治高危NMIBC小样本队列具有持续疗效和耐久性。

研究设计与样本

  • 前瞻性、单臂、开放标签2期试验,纳入25例BCG初治高危NMIBC患者。
  • 患者接受膀胱内Gem/Doce每周6周诱导,随后每月维持治疗2年。
  • 中位随访50个月,所有持续缓解患者至少随访41个月。

主要发现

  • 24个月高级别无复发生存率为84%(21/25;95% CI,63%-94%)。
  • 36个月高级别无复发生存率为80%(20/25;95% CI,58%-91%)。
  • 7例高级别复发中6例接受BCG治疗,其中3例至今无疾病证据。
  • 治疗期间无进展,2例(8%)行膀胱切除术,2例低级别复发。
  • 1级不良事件发生于21例(84%),3级不良事件发生于5例(20%)。

临床怎么用

  • 对于BCG初治高危NMIBC,Gem/Doce可作为一线治疗选择之一,但需注意小样本证据的局限性。
  • 治疗期间应监测不良事件,常见1级事件包括疼痛、疲劳和血尿,3级事件包括血尿和尿路感染。

局限性

  • 单臂设计,样本量小(25例),缺乏对照组。
  • 随访时间仍有限,长期耐久性需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Combination intravesical gemcitabine-docetaxel (Gem/Doce) has demonstrated efficacy in bacillus Calmette-Guérin (BCG)‒unresponsive high-risk (HR) nonmuscle-invasive bladder cancer (NMIBC). However, its efficacy as first-line treatment for BCG-naïve HR NMIBC is unknown. We previously reported recurrence-free survival (RFS) at 1 year. In this article, we present updated 3-year outcomes. MATERIALS AND METHODS: This study is a prospective, single-arm, open-label phase 2 trial for patients with BCG-naïve HR NMIBC. Intravesical Gem/Doce was given weekly for 6 weeks as induction, followed by monthly maintenance therapy for 2 years. We previously reported the primary end point of 3-month complete response, and here, we present secondary end points of 24-month and 36-month high-grade (HG) RFS, along with updated adverse events (AEs). RESULTS: Twenty-five patients were enrolled between August 2020 and August 2022 and followed for a median of 50 months with a minimum of 41-month follow-up in all patients with continued response. The cohort included 16 patients (64%) with HGT1, 8 (32%) with HGTa, and 9 (36%) with carcinoma in situ present. High-grade RFS was 84% at 24 months (21/25; 95% CI, 63%-94%) and 80% at 36 months (20/25; 95% CI, 58%-91%). Recurrences occurred at 11, 11, 15, 20, 36, 49, and 65 months post induction. Six of the 7 patients who had HG recurrence were treated with BCG, and 3 have no evidence of disease to date. No patients had progression during Gem/Doce, and 2 patients (8%) underwent cystectomy: one for recurrence during BCG and another for recurrence after a third-line bladder preservation approach. Two patients had low-grade recurrence. Grade 1 AEs occurred in 21 patients (84%), commonly from pain, fatigue, and hematuria. Five patients (20%) experienced a grade 3 AE including hematuria and UTI. CONCLUSIONS: The updated 3-year results of this single-arm phase 2 trial suggest continued efficacy and durability of Gem/Doce for this small cohort of BCG-naïve HR NMIBC patients.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Garman TS, Lokeshwar S, Campbell J, et al. Phase 2 Trial of Intravesical Gemcitabine and Docetaxel as First-Line Treatment of Bacillus Calmette-Guérin‒Naïve Nonmuscle-Invasive Urothelial Carcinoma: Updated, 3-Year Outcomes. J Urol. 2026. PMID: 42330429. doi:10.1097/JU.0000000000005179

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。